Donate Today Log In

Regenerative Precision Medicine Hero

Regenerative Biology · Precision Health

Restoring Human Potential Through
Regenerative Precision Medicine

Stem Cell Therapy · Tissue Engineering · Cellular Reprogramming · Exosome Biology · Senescence Reversal · Gene Editing

Repair

Not Replace

Cell

Based Therapies

100%

Personalized Protocols

Department Overview

Re·gen·er·
a·tive
Pre·ci·sion

/ rəˈjenərətiv ˈpreSHən ˈmedəsən / · noun

noun · restorative molecular medicine

The precision-guided application of cellular therapies, tissue engineering, and biological repair strategies using each patient's genomic, epigenomic, and stem cell profile to restore damaged or degenerated biological systems rather than merely managing their decline.

Origin

From Latin regenerare (to bring forth again) + praecisio (exactness) + medicina (the healing art). Regenerative precision medicine emerged as the convergence of induced pluripotent stem cell (iPSC) technology pioneered by Yamanaka in 2006 — with CRISPR-based gene correction and single-cell transcriptomics made it possible to engineer patient-matched biological repair strategies targeting the specific molecular defects underlying each individual's tissue failure.

The Regenerative Precision Medicine Department at the American Board of Precision Medicine trains clinicians to understand and apply the emerging frontier of biological restoration integrating stem cell biology, gene therapy vectors, extracellular vesicle signaling, and scaffold-based tissue engineering into individualized treatment architectures guided by each patient's unique cellular and genomic landscape.

From CAR-T cell engineering and iPSC-derived tissue grafts to senolytic clearance protocols, exosome-mediated epigenetic reprogramming, and CRISPR correction of monogenic disease, this department equips physicians with the scientific literacy to evaluate, select, and monitor regenerative interventions distinguishing validated cellular therapies from unproven treatments in a rapidly evolving clinical landscape.

The body retains a profound capacity for repair but that capacity is not uniform. It is molecularly specific, patient-dependent, and time-sensitive. At ABOPM, Regenerative Precision Medicine provides the biological and clinical framework to harness that capacity with precision — matching each patient's repair biology to the intervention most likely to achieve durable, meaningful restoration.

Repair

Not Just Manage

Cell

Matched Therapies

Gene

Level Correction

Regenerative Precision Medicine Department · ABOPM

Where Precision Biology Unlocks
The Body's Capacity for Repair

The Regenerative Precision Medicine Department at ABOPM is redefining what treatment means training physicians to move beyond symptom management and harness the science of biological restoration, integrating stem cell biology, gene therapy, and cellular engineering into individualized repair strategies guided by each patient's unique genomic, epigenomic, and molecular landscape.

Cellular & Gene Therapy

Advancing clinical application of CAR-T cell engineering, iPSC-derived tissue grafts, CRISPR-based gene correction, and senolytic clearance protocols enabling physicians to understand, evaluate, and select precision-guided cellular therapies matched to each patient's specific molecular defects and repair biology.

Epigenomic & Exosome Reprogramming

Bridging molecular biology and clinical restoration developing board-certified frameworks for exosome-mediated epigenetic reprogramming, extracellular vesicle signaling, scaffold-based tissue engineering, and mitochondrial biogenesis protocols that harness the body's endogenous repair machinery with molecular precision.

Physician Education

Building the next generation of regenerative precision physicians through rigorous board standards, stem cell and gene therapy literacy, and interdisciplinary collaboration across molecular biology, clinical genomics, translational pharmacology, bioengineering, and aging science.

"The body retains a profound capacity for repair but that capacity is molecularly specific, patient-dependent, and time-sensitive. The Regenerative Precision Medicine Department at ABOPM trains physicians to harness that capacity with precision, matching each patient's repair biology to the intervention most likely to achieve durable, meaningful restoration."

American Board of Precision Medicine · Regenerative Precision Medicine Department

Become a Member → Support Our Mission → Get Involved →

Regenerative Precision Medicine Department · ABOPM

Matching Each Patient's Repair Biology
to Deliver Restoration, Not Just Management

The human body retains a profound capacity for repair — but that capacity is not uniform, not unlimited, and not randomly distributed. Behind every degenerated tissue, every senescent cell burden, and every treatment-refractory chronic disease lies a specific molecular failure of regenerative biology - genomic defects unrepaired, epigenetic programs locked in dysfunction, stem cell niches depleted, and cellular repair machinery silenced in patterns that conventional pharmacology was never designed to restore. Harnessing each patient's specific regenerative architecture to achieve biological restoration rather than symptom suppression is not a distant aspiration — it is the cellular and genomic obligation of modern precision medicine.

Regenerative precision medicine equips clinicians to move beyond disease management and into the science of biological repair applying stem cell biology, gene therapy, cellular engineering, and epigenomic reprogramming to design patient-matched restoration strategies that address the molecular root causes of tissue failure with a specificity no conventional therapy can provide.

By mastering regenerative precision medicine, clinicians gain the power to:

01

Evaluate and Select Precision Cellular Therapies

Move beyond conventional pharmacology to evaluate, select, and clinically monitor precision-guided cellular therapies applying knowledge of CAR-T cell engineering, iPSC-derived tissue grafts, mesenchymal stem cell applications, and patient-matched cell therapy design to identify which regenerative interventions are validated, which are emerging, and which are unproven noise in a rapidly evolving clinical landscape.

02

Apply Gene Therapy and CRISPR-Based Correction

Integrate understanding of viral and non-viral gene delivery vectors, CRISPR-Cas9 and base editing platforms, and monogenic disease correction strategies to evaluate gene therapy candidacy, interpret therapeutic genomics results, and guide patients through the clinical decision-making framework for gene-level intervention in inherited and acquired disease.

03

Deploy Senolytic and Epigenomic Reprogramming Protocols

Apply senescent cell burden assessment, senolytic agent selection, NAD+ pathway optimization, and exosome-mediated epigenetic reprogramming strategies to address the cellular aging mechanisms that drive tissue degeneration deploying evidence-based biological age reversal protocols grounded in each patient's specific senescence burden and epigenomic profile.

04

Integrate Tissue Engineering and Scaffold Biology

Apply principles of extracellular matrix biology, scaffold-guided tissue regeneration, organoid development, and bioprinting advances to understand and advise on emerging tissue engineering strategies enabling clinicians to evaluate the regenerative medicine pipeline with scientific rigor and guide patients toward evidence-based repair interventions with realistic, molecularly grounded expectations.

05

Lead Regenerative Precision Medicine at Your Institution

Become the regenerative medicine and cellular therapy authority your institution needs - the physician who leads gene and cell therapy evaluation committees, biological age optimization programs, and institutional regenerative medicine initiatives that move patients from passive disease management to active biological restoration grounded in each individual's unique repair biology.

Why Regenerative Precision Medicine Certification Is Non-Negotiable

Every patient has a repair biology. The question is, are you equipped to harness it?

Restoration-Driven Outcomes

Precision-guided regenerative strategies consistently outperform symptom management in tissue failure, inherited disease, and biological aging delivering measurably better outcomes by addressing the molecular root causes of cellular dysfunction and repair failure rather than suppressing their downstream clinical manifestations with indefinite pharmacological management.

Future-Ready Practice

CAR-T and CAR-NK therapies, iPSC-derived organoids, in vivo CRISPR delivery, senolytic drugs, and epigenetic reprogramming agents are moving from research to routine clinical application - physicians board-certified in regenerative precision medicine will define the next frontier of biological restoration in clinical practice.

Clinical Authority

Board certification in regenerative precision medicine marks you as the cellular therapy and biological repair authority - a physician equipped to lead gene and cell therapy programs, longevity medicine clinics, and institutional regenerative medicine initiatives that responsibly translate the cutting edge of repair biology into clinical outcomes.

Cross-Disease Impact

Regenerative precision medicine principles apply universally across hematology, oncology, neurology, musculoskeletal medicine, cardiovascular disease, and aging science giving you a biology-first restoration framework to address the molecular root causes of tissue failure across every specialty and patient population you serve.

Active research areas driving regenerative precision medicine forward:

01

iPSC Biology & Patient-Matched Cell Therapy

Advancing the clinical translation of induced pluripotent stem cell technology — developing iPSC reprogramming protocols, directed differentiation methods, and quality control frameworks that enable the generation of patient-matched cardiomyocytes, neurons, hepatocytes, and pancreatic beta cells for disease modeling, drug screening, and precision tissue replacement strategies grounded in each patient's individual genomic and epigenomic architecture.

02

CRISPR Gene Correction & In Vivo Delivery

Pushing the frontiers of CRISPR-Cas9, base editing, and prime editing for monogenic disease correction — developing high-fidelity editing strategies, off-target detection methods, and in vivo delivery vehicles (lipid nanoparticles, AAV vectors, and next-generation non-viral carriers) that achieve therapeutic gene correction with the efficiency, precision, and safety profile required for clinical deployment across inherited hematological, metabolic, and neuromuscular disease.

03

CAR-T, CAR-NK & Next-Generation Cellular Immunotherapy

Advancing the design, manufacturing, and clinical deployment of next-generation CAR-T and CAR-NK cell therapies — developing logic-gated CAR constructs, armored cell designs, universal allogeneic platforms, and tumor microenvironment resistance strategies that extend cellular immunotherapy efficacy beyond hematological malignancies to solid tumors, autoimmune disease, and aging-associated tissue dysfunction.

04

Senolytic Therapy & Epigenetic Reprogramming

Building the preclinical and clinical evidence base for senolytic drug combinations, partial epigenetic reprogramming protocols, and NAD+ pathway restoration strategies — developing validated senescent cell burden quantification methods, optimal senolytic dosing and timing frameworks, and epigenetic reprogramming safety parameters that enable the translation of biological age reversal science into responsible, evidence-based clinical practice.

05

Tissue Engineering & Extracellular Vesicle Therapeutics

Advancing scaffold-guided tissue regeneration, organoid-based disease modeling, and extracellular vesicle therapeutic platforms — developing bioprinted tissue constructs, decellularized matrix scaffolds, and exosome-mediated epigenetic signaling delivery systems that harness endogenous repair biology to achieve durable, precision-guided tissue restoration across musculoskeletal, cardiac, hepatic, and neurological disease applications.

Regenerative Precision Medicine Research · ABOPM

Harnessing Biology's Repair Capacity to Restore, Not Just Manage

The regenerative medicine revolution is not a future event — it is rewriting what treatment means today. iPSC-derived cell therapies, CRISPR gene correction, CAR-T cellular immunotherapy, senolytic drug development, and extracellular vesicle platforms are actively transforming how tissue failure, inherited disease, and biological aging are addressed at the molecular and individual patient level — moving medicine from management to restoration.

The ABOPM Regenerative Precision Medicine Department positions clinicians at the center of this transformation — equipping them with the stem cell biology literacy, gene and cell therapy evaluation frameworks, and board-certified credentials to lead precision biological restoration programs across every disease domain and patient population.

$130B

Global regenerative medicine market projected by 2030

1,000+

Gene and cell therapy clinical trials currently active

Repair

Not management — the new standard of precision biological care

Explore Blog Topics → Read clinical insights, case studies & regenerative precision medicine updates on our blog

Regenerative Precision Medicine Department · ABOPM

Meet Our Leadership

Director of Regenerative Precision Medicine

Director

Regenerative Precision Medicine

Director of Regenerative Precision Medicine Inaugural President · American Academy of Regenerative Medicine

Joseph Purita, MD, FACS, FAAOS, FAASCP

Board-Certified Orthopedic Surgeon · Cellular & Anti-Aging Therapies · Georgetown University

"Pioneering advancements in regenerative medicine — helping patients achieve optimal health and longevity through cutting-edge cellular therapies developed over more than two decades at the frontier of biological repair."

Dr. Purita is a board-certified orthopedic surgeon with over 20 years of expertise in cellular and anti-aging therapies within the field of Regenerative Medicine. He completed his medical education and training at Georgetown University and has since become a globally recognized leader in advancing innovative treatment approaches.

He served as the inaugural president of the American Academy and Board of Regenerative Medicine and currently serves as Medical Director of Pur-Form and its nationwide network. His contributions include numerous scientific publications and book chapters, and he was recently appointed Professor of Regenerative Medicine at the University of Max Planck in Indaiatuba, Brazil — a sought-after speaker who has lectured extensively worldwide on regenerative medicine and cellular therapies.

20+

Years in Regenerative Medicine

1st

President · American Academy of Regenerative Medicine

Global

Speaker & Professor

Connect on LinkedIn

Faculty Members

Our faculty roster is growing — announcements coming soon.

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Coming Soon

Faculty position open

Think you're the right fit for a faculty position?

Get Involved →

Genomics Department · ABOPM

Shaping the Future
of Precision Medicine

As precision medicine continues to evolve, genomics will play an increasingly central role in redefining how disease is understood, predicted, and treated at the molecular level.

The Genomics Department at ABOPM remains committed to advancing this field through scientific leadership, clinical innovation, and collaborative discovery. Together with our global community of physicians and researchers, we are helping shape the future of next-generation healthcare.

Explore Certification → Get Involved

Featured Insights

Insights Shaping
Precision Medicine

Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.

Multi-Omics Clinical Innovation Precision Prevention Physician Leadership

Liquid Biopsy and Early Cancer Detection: Promise and Limitations

Liquid biopsy is transforming cancer detection through minimally invasive genomic testing, offering new opportunities for earlier diagnosis and monitoring. ...more

Precision Oncology

June 05, 2026•9 min read

Polygenic Risk Scores and the Genomic Data Gap: Promise, Limitations, and Equity in Precision Medicine

Polygenic risk scores may transform disease prediction, but gaps in genomic diversity continue to limit equity, accuracy, and access in precision medicine across global populations. ...more

Population Precision

May 26, 2026•9 min read

Artificial Intelligence in Precision Medicine

Artificial intelligence is reshaping precision medicine by improving diagnostics, predicting treatment response, and enabling more personalized, data-driven healthcare strategies. ...more

On the Frontier

May 20, 2026•9 min read